Skip to main content
. 2020 Nov 25;26(3):e367–e373. doi: 10.1002/onco.13582

Figure 1.

Figure 1

Kaplan‐Meier plots: percentage survival. (A): Impact of treatment cycles on the clinical outcomes. (B): Chemotherapy‐naïve evaluable patients with hepatocellular carcinoma and hepatitis B virus benefited most with PHY906 plus capecitabine drug treatment (combination of both U.S. and Taiwan studies).Abbreviations: CI, confidence interval; HR, hazard ratio; mOS, median overall survival.